What lies ahead for Victoria’s healthtech sector in 2022 and beyond?
Our annual Hot or Not event, delivered in partnership with Phillips Ormonde Fitzpatrick, will explore hot trends in the sector with a selection of speakers each presenting a snapshot of what’s HOT in their areas of expertise.
Showcasing the growth and advancement of therapeutic psychedelics, AI-driven medical technology, drug development and biotechnology, our speakers will examine the following hot topics:
The (re)emerging field of therapeutic psychedelics – clinical trials and commercial interest suggest they are hot but regulatory approval in Australia is indicting not…yet.
Automated auscultation for neonatal health monitoring – a novel neonatal-specific respiratory assessment technique powered by artificial intelligence.
The new era of drug development – human, 3D neural micro-tissue platform enabling pharmaceutical companies to discover safer and more effective drugs for neurological disease.
Synthetic biology – one of the fastest growing areas of modern science.
Date: Tuesday 19 July 2022 Time: 4:00 pm – 5:30 pm AEST Presentations and Q&A
5:30 pm – 6:30pm Networking (in person guests only) Venue: Phillips Ormonde Fitzpatrick, Level 16, 333 Collins Street, Melbourne Format (online & in person): An access link will be provided prior to the event.
Dr Mark Wickham, Principal, Patent and Trade Marks Attorney, Phillips Ormonde Fitzpatrick Dr Faezeh Marzbanrad, Lecturer, Monash University Dr Christos Papadimitriou, CEO & Managing Director, Tessara Therapeutics Dr Charlotte Williams, Group Leader, CSIRO Biomedical Manufacturing
Dr Mark Wickham, Principal, Patent and Trade Marks Attorney, Phillips Ormonde Fitzpatrick
Mark's work focuses on the preparation and prosecution of patent applications in Australia and internationally, due diligence, freedom to operate and invalidity advice for the pharmaceutical, biotechnology, health and medical device industries.
Mark majored in genetics, biochemistry and molecular biology for his BSc(Hons) at the University of Melbourne, and his PhD work at the Walter and Eliza Hall Institute with Alan Cowman FRS focussed on the molecular and cellular biology of malaria.
Mark conducted four years of postdoctoral research at the Michael Smith Laboratories (named for its Nobel Prize-winning Director) at the University of British Columbia in Canada. His work focussed on the immunologic and inflammatory responses to infectious agents at the molecular and cellular level. Upon returning to Australia as part of a CJ Martin Fellowship, Mark conducted further post-doctoral research at the Walter and Eliza Hall Institute.
As a result of his scientific research, Mark has 33 publications in peer reviewed international journals, including Cell, EMBO Journal, PNAS and Current Biology. Mark has also published on issues in intellectual property in Nature Biotechnology and Nature Reviews Drug Discovery. His research has been cited over 5,000 times.
Mark is a passionate advocate for science and technology in Australia, and has sat on the advisory boards of a number of technology based start-up companies. He is a mentor at the Melbourne Accelerator Program, Australia’s leading start-up accelerator, and is a mentor at Industry Mentoring Network in Stem (IMNIS), a mentoring program connecting PhD students with industry leaders in a one year mentoring program. He is also a guest lecturer in the commercialisation of science at the University of Melbourne.
Mark joined Phillips Ormonde Fitzpatrick in 2007, and became a Principal of the firm in 2015. Mark is a registered Australian and New Zealand Patent Attorney.
Dr Faezeh Marzbanrad, Lecturer, Monash University
Dr Faezeh Marzbanrad joined the Electrical and Computer Systems Engineering (ECSE) Department of Monash University in June 2016, where she is currently a lecturer. She completed her Ph.D. in Electrical and Electronic Engineering at the University of Melbourne in May 2016, with IPRS and APA scholarships funded by the Australian Government.
She was awarded Victoria Fellowship by Veski and the Victorian Government in 2021 and received Women Leading Tech Award in Education/Research category in 2022. Her research interests include biomedical signal processing, machine learning, medical devices, health equity, mobile-health as well as foetal, maternal and neonatal healthcare technologies
Dr Christos Papadimitriou, CEO & Managing Director, Tessara Therapeutics
Dr Christos Papadimitriou is the CEO and Managing Director of Tessara Therapeutics. A serial entrepreneur, Christos is an award-wining qualified neuroscientist with solid experience in commercialisation.
He has been working in the field of regenerative medicine at world-class institutes, including Johns Hopkins Medical School, ETH Zurich, EMBL Heidelberg and the German Center for Neurodegenerative Diseases, to develop regenerative medicine applications with commercial focus. Christos is highly skilled at identifying commercial opportunities and creating spin-out entities to commercialise new IP in the pharmaceuticals and health-care space.
Dr Charlotte Williams, Group Leader, CSIRO Biomedical Manufacturing
Dr Charlotte Williams is a Principal Research Scientist within the Biomedical Manufacturing Program at CSIRO. A synthetic chemist with a keen focus on synthetic biology, Charlotte leads the Chemical Biology, Diagnostics & Devices Group within the Manufacturing Business Unit. Charlotte regularly engages Australian Industries to deliver value to the Australian Biotechnology community and collaborates widely with Australian universities.
Expertise in synthetic chemistry and conjugation of small molecules, proteins and antibodies, polymer synthesis and polymer bioconjugation.
Charlotte completed her PhD from the University of Western Australia, followed by a postdoctoral fellowship at The University of Oxford, from there she gained industry experience both in the UK and Australia before taking up a role at CSIRO in 2009